Medical isotope developer IsoRay Medical reported that market acceptance of its cesium-131 brachytherapy products continued to advance.
There are now 51 active sites recently added that are either accredited to provide the product, in the process of getting licensed for cesium-131 use, or are in advanced discussions to adopt it, according to the Richland, WA-based company. IsoRay said that this brings the total to 142 sites that are utilizing or in the process to apply the isotope for brachytherapy treatment of prostate cancer.
By AuntMinnie.com staff writers
April 5, 2007
Related Reading
IsoRay scores additional financing, March 23, 2007
IsoRay adds cesium-131 sites, January 17, 2007
IsoRay sales triple in fiscal Q1, November 15, 2006
IsoRay reaches seed century mark, October 17, 2006
IsoRay promotes Hunt to CFO, raises seed prices, September 12, 2006
Copyright © 2007 AuntMinnie.com
